Exicure Inc

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. Its product pipeline include Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Skokie, IL.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Akebia Therapeutics

Astra Space

SoFi Technologies

Volitionrx Limited

X4 Pharmaceuticals Inc

Insiders are buying these penny stocks but are they worth the risk? The post Penny Stocks To Buy: 6 Insider Picks Before 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy: 6 Insider Picks Before 2023

Insiders are buying these penny stocks but are they worth the risk? The post 3 Top Penny Stocks To Buy According To Insiders Before 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Top Penny Stocks To Buy According To Insiders Before 2023

CHICAGO--( BUSINESS WIRE )--Exicure, Inc. (NASDAQ: XCUR) an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced the termination of its collaboration agreements with AbbVie, Inc. (AbbVie) and Ipsen BioPharm Limited (Ipsen).

Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements

CHICAGO--( BUSINESS WIRE )--Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today reported financial results for the quarter ended September 30, 2022 and provided an update on its business strategy and corporate progress.

Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

CHICAGO--(BUSINESS WIRE)--Exicure announced plans to restructure the Company and align resources to continue exploring strategic alternatives that maximize stockholder value.

Exicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives

CHICAGO--(BUSINESS WIRE)--Exicure CEO Matthias Schroff will provide a live presentation at the 2022 Chardan Genetic Medicines Conference.

Exicure Announces Presentation at Chardan's 6th Annual Genetic Medicines Conference

CHICAGO--(BUSINESS WIRE)--Exicure today reported financial results for the quarter ended June 30, 2022 and provided an update on its business strategy and corporate progress.

Exicure, Inc. Reports Second Quarter 2022 Financial Results and Corporate Progress

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that on July 19, 2022, it received a letter from the Office of General Counsel of The Nasdaq Stock Market LLC informing it that Nasdaq has confirmed that the Company has regained compliance with the $1.00 per share mini

Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

A reverse stock split of Exicure, Inc. (NASDAQ: XCUR) of 1-for-30 has gone into effect. These are the details.

Exicure (XCUR) Stock: 1-For-30 Reverse Split Goes Into Effect

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that, following the implementation of a one-for-thirty reverse stock split at 5:00 p.m. EDT today, the Company's common stock will begin trading on a split-adjusted basis on Nasdaq effective with the open of business to

Exicure, Inc. Announces Receipt of Nasdaq Notice of Non-compliance and Implementation of One-for-Thirty Reverse Stock Split

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that the Company's Annual Meeting of Stockholders (the “Annual Meeting”) held in virtual format on Friday, May 27, 2022 at 1:00 p.m. Central Time, was convened and adjourned until June 10, 2022 at 1:00 p.m. Central Time

Exicure, Inc. Announces Adjournment of Annual Meeting of Stockholders

BitNile Holdings

Waitr Holdings Inc

Here's what you need to know about trading penny stocks today The post What to Know About Buying Penny Stocks on May 20th  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Buying Penny Stocks on May 20th

CHICAGO--(BUSINESS WIRE)--Exicure today announced that CEO Matthias Schroff will provide a virtual presentation at the 2022 H.C. Wainwright Global Life Sciences Conference.

Exicure Announces Presentation at 2022 H.C. Wainwright Global Life Sciences Conference

CHICAGO--(BUSINESS WIRE)--Exicure today reported financial results for the quarter ended March 31, 2022 and provided an update on its business strategy and corporate progress.

Exicure, Inc. Reports First Quarter 2022 Financial Results and Corporate Progress

CHICAGO--(BUSINESS WIRE)--Exicure, Inc.® (NASDAQ:XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that it has agreed to sell an aggregate of 26,021,111 shares of its common stock at a purchase price of $0.1937 per share to certain accredited investors in a private placement in public equity (“PIPE”) financing. The p

Exicure Announces $5 Million Raise in Private Placement Transaction Priced at Market Premium

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. today announced a poster presentation at TIDES USA 2022, May 9-12, 2022.

Exicure to Present at Upcoming TIDES USA Oligonucleotide & Peptide Therapeutics Conference

Transocean

China Rapid Finance

Here are three penny stocks to add to your watchlist this week The post Check These 3 Hot Penny Stocks Out For Your List This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Check These 3 Hot Penny Stocks Out For Your List This Week

Exicure Inc (NASDAQ: XCUR) has reported year-end cash, cash equivalents, and short-term investments of $48.3 million that will fund its current operations into Q4 of 2022. The Company said that it expects to continue to generate operating losses and negative operating cash.

Exicure Shares Plunge After Q4 Results Included A Going Concern Risk

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today reported full year financial results for the quarter and year ended December 31, 2021 and provided an update on its business strategy and corporate progress. “This past year brought significant challenges to our organization that prompted strategic decisions at year-end to refocus our business strategy on our next generation p

Exicure, Inc. Reports Full Year 2021 Financial Results and Corporate Progress

Clearside Biomedical

Arcadia Biosciences

Check these trending penny stocks out for your watchlist The post Good Trending Penny Stocks to Buy Now? Check These 3 Out  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Good Trending Penny Stocks to Buy Now? Check These 3 Out

Guardion Health Sciences Inc

Kiromic Biopharma

Powerbridge Technologies Co Ltd

Penny stocks to watch under $1 this week. The post 4 Top Penny Stocks To Buy For Under $1 This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Top Penny Stocks To Buy For Under $1 This Week

San Diego, California--(Newsfile Corp. - February 17, 2022) - Johnson Fistel, LLP is investigating potential claims on behalf of Exicure, Inc. ("Exicure" or the "Company") (NASDAQ: XCUR) against certain of its officers and directors.Recently, a class action complaint was filed against Exicure. According to the complaint, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically,...

Did You Acquire (XCUR) Before January 7, 2021? Should Management Be Held Accountable for Investors Losses?

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Exicure To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - February 11, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Exicure, Inc. ("Exicure" or the "Company") (NASDAQ: XCUR) and reminds investors of the February 11, 2022 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $100,000 investing in Exicure stock or options...

Exicure Shareholder Alert

New York, New York--(Newsfile Corp. - February 10, 2022) -  Pomerantz LLP is investigating claims on behalf of investors of Exicure, Inc. ("Exicure" or the "Company") (NASDAQ: XCUR). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Exicure and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exicure, Inc. - XCUR

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming February 11, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Exicure, Inc. (“Exicure” or the “Company”) (NASDAQ: XCUR) securities between January 7, 2021 and December 10, 2021, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On November 15, 2021, after the market closed, Exicure filed

News for Exicure Inc Stock (XCUR)